Alembic Pharmaceuticals Incorporates German Subsidiary Under SEBI Regulation 30
Alembic Pharmaceuticals Limited has incorporated a wholly owned subsidiary, Alembic Pharmaceuticals GmbH, in Germany with EUR 25,000 share capital divided into 25,000 shares. The subsidiary, established to explore new business opportunities and distribute pharmaceutical products in the German market, operates under full SEBI regulatory compliance with 100% ownership by the parent company.
*this image is generated using AI for illustrative purposes only.
Alembic Pharmaceuticals Limited has announced the incorporation of a wholly owned subsidiary in Germany, marking its strategic expansion into the European pharmaceutical market. The company informed the stock exchanges on 23 April 2026 about the establishment of Alembic Pharmaceuticals GmbH under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Subsidiary Details and Structure
The newly incorporated German subsidiary has been established with specific financial parameters designed to support its operations in the European market.
| Parameter: | Details |
|---|---|
| Company Name: | Alembic Pharmaceuticals GmbH |
| Share Capital: | EUR 25,000 |
| Number of Shares: | 25,000 shares |
| Par Value: | EUR 1.00 per share |
| Ownership: | 100% by Alembic Pharmaceuticals Limited |
| Current Turnover: | Nil (yet to commence operations) |
Business Objectives and Strategic Purpose
The incorporation aims to explore new business opportunities in the German geography to promote, sell, and distribute pharmaceutical products of the parent company. This expansion represents Alembic's commitment to strengthening its presence in international markets, particularly in Europe's robust pharmaceutical sector.
The subsidiary operates in the pharmaceuticals industry, aligning with the parent company's core business activities. As a newly incorporated entity, it is yet to commence business operations and currently reports nil turnover.
Regulatory Compliance and SEBI Disclosure
The company has fulfilled all disclosure requirements under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as specified in Para A of Part A of Schedule III. The formal communication was signed by Company Secretary Manisha Saraf and submitted to both BSE Limited and National Stock Exchange of India Ltd.
| Compliance Aspect: | Status |
|---|---|
| Related Party Transaction: | Not Applicable |
| Governmental Approvals: | Not Applicable |
| Consideration Type: | Investment in Share Capital |
| Control Acquired: | 100% shareholding |
| Industry Classification: | Pharmaceuticals |
Strategic Market Expansion
This incorporation represents a strategic move to capitalize on opportunities in the German pharmaceutical market while maintaining full operational control through its wholly owned subsidiary structure. The establishment of Alembic Pharmaceuticals GmbH positions the company to directly engage with European customers and regulatory authorities, potentially enhancing its market reach and operational efficiency in the region.
The subsidiary's focus on promoting, selling, and distributing pharmaceutical products aligns with Alembic's core business strategy of expanding its global footprint in key international markets.
Historical Stock Returns for Alembic Pharmaceuticals
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.54% | +4.62% | +13.50% | -17.59% | -10.17% | -23.50% |
What specific pharmaceutical products does Alembic plan to prioritize for the German market launch?
How will this European expansion impact Alembic's overall revenue projections for the next 2-3 years?
What regulatory hurdles must Alembic navigate to gain market authorization for its products in Germany?
18
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
